Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 849

Sort by

Sort Order Select

Journal Articles

Genetic characterization of B-cell prolymphocytic leukemia: a prognostic model involving MYC and TP53

Blood (2019) 134 (21): 1821–1831.

https://doi.org/10.1182/blood.2019001187

Published: 2019

Includes: Supplemental data

Journal Articles

Diagnostic Testing Patterns and Concordance with World Health Organization (WHO) Criteria for Patients (Pts) with Newly Diagnosed (ND) Myelodysplastic Syndromes (MDS) in the Connect ® MDS/AML Registry

Tracy I. George, MD, Christopher R. Cogle, MD, Guillermo Garcia-Manero, MD, David L. Grinblatt, Rami Komrokji, Michael R. Savona, MD, Bart L. Scott, MD, Mikkael A. Sekeres, MD MS, David P. Steensma, MD, E. Dawn Flick, Pavel Kiselev, Chrystal U. Louis, Melissa Nifenecker, Arlene S. Swern, Kathryn Foucar

Blood (2019) 134 (Supplement_1): 4747.

https://doi.org/10.1182/blood-2019-122913

Published: 2019

Journal Articles

Exome Sequencing of Relapsed Multiple Myeloma Combined with Pooled CRISPR/Cas9 Screens Identifies Gene Mutations Associated with Drug-Specific Resistance

Stephan Bohl, Laura K. Schmalbrock, MD, Imke Bauhuf, Anna Dolnik, Tamara J. Blätte, MSc, Stefanie Lindner, Dr., Tatjana Meyer, MSc, BSc, Sarah Knödler, Denise Miller, Miriam Kull, Christian Langer, MD, Hartmut Döhner, MD, Dirk Heckl, PhD, Lars Bullinger, Jan Krönke, MD

Blood (2019) 134 (Supplement_1): 809.

https://doi.org/10.1182/blood-2019-131245

Published: 2019

Journal Articles

Mutational Patterns and Clonal Architecture of Therapy-Related Acute Myeloid Leukemia

Hassan Awada, Teodora Kuzmanovic, Ashwin Kishtagari, MBBS, Jibran Durrani, Arda Durmaz, Sanghee Hong, MD, Cassandra M Kerr, MS, Vera Adema, PhD, Yihong Guan, PhD, Sonia Sandhu, Aziz Nazha, MD, Manja Meggendorfer, PhD, Torsten Haferlach, MD, Hetty E. Carraway, MD MBA, Mikkael A. Sekeres, MD MS, Valeria Visconte, PhD, Jaroslaw P. Maciejewski, MD PhD

Blood (2019) 134 (Supplement_1): 1405.

https://doi.org/10.1182/blood-2019-131953

Published: 2019

Journal Articles

Single Nucleotide Polymorphism Array-Based Signature of Genetic Ploidy Groups in Acute Lymphoblastic Leukemia

Thomas Creasey, MBBS, Amir Enshaei, PhD, Kathryn Watts, BSc, Gavin Cuthbert, BSc, Claire Schwab, PhD, Christine J. Harrison, PhD FRCPath, Ajay Vora, Adele K. Fielding, MBBS,PhDFRCP,FRCPath, Anthony V. Moorman

Blood (2019) 134 (Supplement_1): 1473.

https://doi.org/10.1182/blood-2019-122556

Published: 2019

Journal Articles

Use of Machine Learning in 2074 Cases of Acute Myeloid Leukemia for Genetic Risk Profiling

Shaun Fleming, MBBS,, Cheng-Hong Tsai, MD MSc, Hartmut Döhner, MD, Konstanze Döhner, Elli Papaemmanuil, PhD, Hwei-Fang Tien, MD, PhD, John Reynolds, PhD, Andrew H. Wei, PhD FRACP, FRCPA, MBBS, Hsin-An Hou

Blood (2019) 134 (Supplement_1): 1392.

https://doi.org/10.1182/blood-2019-128243

Published: 2019

Journal Articles

Biomarker Modulation By Mivebresib (ABBV-075) +/- Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia

Gautam M. Borthakur, MD, Olatoyosi Odenike, MD, Ibrahim Aldoss, MD, David A. Rizzieri, MD, Thomas Prebet, MD PhD, Dimple A. Modi, PhD, Rujuta Joshi, Beibei Hu, Yan Sun, PhD, Johannes E. Wolff, MD, Brian A Jonas, MD PhD

Blood (2019) 134 (Supplement_1): 539.

https://doi.org/10.1182/blood-2019-126854

Published: 2019

Journal Articles

Next-Generation RNA Sequencing-Based Analysis Identifies a Novel Set of Prognostic Micrornas (miRs) in Cytogenetically Normal Acute Myeloid Leukemia (CN-AML)

Dimitrios Papaioannou, MD, Deedra Nicolet, MS, Kellie J Archer, PhD, Allison Walker, Krzysztof Mrózek, MD PhD, Andrew J. Carroll, PhD, Jessica Kohlschmidt, PhD, Ann-Kathrin Eisfeld, MD, Marius Bill, MD PhD, Christopher J. Walker, PhD, Geoffrey L. Uy, MD, Bayard L Powell, MD, Jonathan E. Kolitz, MD, Richard Stone, MD, John C. Byrd, MD, Ramiro Garzon, MD, Clara D. Bloomfield, MD

Blood (2019) 134 (Supplement_1): 2694.

https://doi.org/10.1182/blood-2019-125727

Published: 2019

Journal Articles

Characteristics and Outcome of Patients with Core Binding Factor Acute Myeloid Leukemia and FLT3 -ITD: Results from an International Collaboration

Sabine Kayser, MD, Michelle A Elliott, MD, Marlise Luskin, MDMS, Andrew M. Brunner, MD, Michael Kramer, M.Sc., Zdenek Racil, MD, Zuzana Sustkova, MD, Petr Cetkovsky, MD MBA, PhD, Jan Novak, MD PhD, Friedrich Stoelzel, MD, Christian Thiede, MD, Carsten Müller-Tidow, MD, Uwe Platzbecker, Christoph Röllig, MD MSC, Richard F. Schlenk, MD, Mark J. Levis, MD

Blood (2019) 134 (Supplement_1): 2693.

https://doi.org/10.1182/blood-2019-125317

Published: 2019

Journal Articles

Trial in Progress: Feasibility and Validation Study of the LSC17 Score in Acute Myeloid Leukemia Patients

Tracy Murphy, MDFRCP,FRCPath, Stanley W.K. Ng, PhD, Tong Zhang, Ian King, PhD, Andrea Arruda, Jaime O. Claudio, PhD, Narmin Ibrahimova, Fiona Ferrera, Chantal Rockwell, Zhibin Lu, Natalie Stickle, Carl Virtanen, MSc, Brian Leber, MD, Mitchell Sabloff, MD, Mark D. Minden, MD PhD, Tracy L. Stockley, PhD FCCMG, FACMG, Steven M Chan, MD PhD, Jean C.Y. Wang, MD

Blood (2019) 134 (Supplement_1): 2682.

https://doi.org/10.1182/blood-2019-130532

Published: 2019

Journal Articles

Venetoclax Combined with Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Produces High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Blood (2019) 134 (Supplement_1): 2647.

https://doi.org/10.1182/blood-2019-122477

Published: 2019

Journal Articles

A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Older Patients with Acute Myeloid Leukemia (AML) Undergoing Remission Induction Therapy

Sudipto Mukherjee, MD PhD MPH, Hong Li, Brian P. Hobbs, PhD, Aaron T. Gerds, MD MS, Anjali S. Advani, MD, Hetty E. Carraway, MD MBA, Aziz Nazha, MD, Samjhana Bogati, RN, Eric Parsons, RN, Benjamin Pannell, Matt Kalaycio, MD, Yogenthiran Saunthararajah, MD, Jaroslaw P. Maciejewski, MD PhD, Mikkael A. Sekeres, MD MS

Blood (2019) 134 (Supplement_1): 2595.

https://doi.org/10.1182/blood-2019-132178

Published: 2019

Journal Articles

Clinical Interest of LMO2 Testing in Aggressive Large B-Cell Lymphomas

Luis Colomo, Ivonne Vazquez, Natalia Papaleo, Marta Salido, Anna Puiggros, Blanca Espinet, Maria Rodriguez-Rivera, Ramon Diez-Feijoo, Blanca Sanchez-Gonzalez, Antonio Salar, Ana Ferrer, Leonor Arenillas, Marcio Andrade Campos, MD PhD, Xavier Calvo

Blood (2019) 134 (Supplement_1): 2899.

https://doi.org/10.1182/blood-2019-125717

Published: 2019

Journal Articles

Differentiating between Hyperdiploidy and Pseudo-Hyperdiploidy in B-Lymphoblastic Leukemia Utilizing Low-Coverage Mate-Pair Sequencing

James B Smadbeck, Beth A Pitel, MA, Kathryn E. Pearce, Sarah H Johnson, MS, Nicole Hoppman, Rhett P. Ketterling, MD, Patricia Griepp, MD, Linda B Baughn, PhD, George Vasmatzis, PhD, Jess Peterson, MD

Blood (2019) 134 (Supplement_1): 5212.

https://doi.org/10.1182/blood-2019-122440

Published: 2019

Journal Articles

Next-Generation Optical Mapping Reveals Numerous Previously Unrecognizable Structural Variants in Chronic Lymphocytic Leukemia

Regina Fillerova, PhD, Anna Petrackova, MSc, Tomas Papajik, MD prof, Peter Turcsanyi, MD PhD, Marek Behalek, PhD, Petr Gajdos, PhD assoc prof, Pavlina Ryznerova, MD, Lenka Kruzova, MA, Helena Urbankova, MSc, PhD, Jiri Minarik, MD PhD, Eva Kriegova, Dr, assoc prof

Blood (2019) 134 (Supplement_1): 5450.

https://doi.org/10.1182/blood-2019-127993

Published: 2019

Journal Articles

Genomic Analysis of Therapy-Related Myeloid Neoplasms and Tracking of the Founder Clone By Circulating Tumor DNA

Kanya Kondoh, MD, Kazuaki Yokoyama, MD PhD, Nozomi Yusa, Mika Ito, Eigo Shimizu, Sousuke Nakamura, MD, Miho Ogawa, MD, Tomomi Takei, MD, Asako Kobayashi, Rika Kasajima, PhD, Yuka Wada, Rui Yamaguchi, PhD, Seiya Imoto, PhD, Tokiko Nagamura-Inoue, MD PhD, Kaoru Uchimaru, MD, PhD, Satoru Miyano, PhD, Arinobu Tojo, MD PhD

Blood (2019) 134 (Supplement_1): 5393.

https://doi.org/10.1182/blood-2019-127611

Published: 2019

Journal Articles

Creating and Testing a CD207+ Langerhans Cell Histiocytosis-like Cell Line

Jessica Velazquez, BS, Amel Sengal, BS, Carl E. Allen, MD PhD, Rikhia Chakraborty, PhD

Blood (2019) 134 (Supplement_1): 5399.

https://doi.org/10.1182/blood-2019-130588

Published: 2019

Journal Articles

Clinical and Prognostic Impact of (11;14)(q13;q32) Translocation on Patients with Multiple Myeloma

Daisuke Miura, MD, Kentaro Narita, MD, Ayumi Kuzume, MD, Rikako Tabata, MD, Toshiki Terao, MD, Takafumi Tsushima, MD, Hiroki Kobayashi, MD, Yoshiaki Abe, MD, Akihiro Kitadate, MD PhD, Masami Takeuchi, MD, Kosei Matsue, MD PhD

Blood (2019) 134 (Supplement_1): 5507.

https://doi.org/10.1182/blood-2019-130809

Published: 2019

Journal Articles

A Prospective Observational Study of Clinico-Pathological Features, Prognostic Factors and Treatment Response to Primary Therapy in Multiple Myeloma at a Tertiary Care Centre

Saurabh Mishra, MD DNB, Ashok K Vaid, MDDM, Nitin Sood, MDFRCPath,MRCP, Manorama Bhargava, Bhuvan Chugh, DNB, Roshan Dixit, MD, Amrita Ramaswami, MDDM, Devender Sharma, MD

Blood (2019) 134 (Supplement_1): 5559.

https://doi.org/10.1182/blood-2019-125752

Published: 2019

Journal Articles

Second-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia with Additional Chromosomal Abnormalities

Naoto Takahashi, MD PhD, Tomoko Yoshioka, MD, Masahiro Kizaki, MD, Tatsuya Kawaguchi, MD, Ritsuro Suzuki, MD PhD, Kazuhito Yamamoto, Kazunori Ohnishi, MD, Tomoki Naoe, MD PhD, Itaru Matsumura, MD PhD

Blood (2019) 134 (Supplement_1): 1640.

https://doi.org/10.1182/blood-2019-123337

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Genetic characterization of B-cell prolymphocytic leukemia: a prognostic model involving MYC and TP53

Diagnostic Testing Patterns and Concordance with World Health Organization (WHO) Criteria for Patients (Pts) with Newly Diagnosed (ND) Myelodysplastic Syndromes (MDS) in the Connect ® MDS/AML Registry

Exome Sequencing of Relapsed Multiple Myeloma Combined with Pooled CRISPR/Cas9 Screens Identifies Gene Mutations Associated with Drug-Specific Resistance

Mutational Patterns and Clonal Architecture of Therapy-Related Acute Myeloid Leukemia

Single Nucleotide Polymorphism Array-Based Signature of Genetic Ploidy Groups in Acute Lymphoblastic Leukemia

Use of Machine Learning in 2074 Cases of Acute Myeloid Leukemia for Genetic Risk Profiling

Biomarker Modulation By Mivebresib (ABBV-075) +/- Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia

Next-Generation RNA Sequencing-Based Analysis Identifies a Novel Set of Prognostic Micrornas (miRs) in Cytogenetically Normal Acute Myeloid Leukemia (CN-AML)

Characteristics and Outcome of Patients with Core Binding Factor Acute Myeloid Leukemia and FLT3 -ITD: Results from an International Collaboration

Trial in Progress: Feasibility and Validation Study of the LSC17 Score in Acute Myeloid Leukemia Patients

Venetoclax Combined with Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Produces High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Older Patients with Acute Myeloid Leukemia (AML) Undergoing Remission Induction Therapy

Clinical Interest of LMO2 Testing in Aggressive Large B-Cell Lymphomas

Differentiating between Hyperdiploidy and Pseudo-Hyperdiploidy in B-Lymphoblastic Leukemia Utilizing Low-Coverage Mate-Pair Sequencing

Next-Generation Optical Mapping Reveals Numerous Previously Unrecognizable Structural Variants in Chronic Lymphocytic Leukemia

Genomic Analysis of Therapy-Related Myeloid Neoplasms and Tracking of the Founder Clone By Circulating Tumor DNA

Creating and Testing a CD207+ Langerhans Cell Histiocytosis-like Cell Line

Clinical and Prognostic Impact of (11;14)(q13;q32) Translocation on Patients with Multiple Myeloma

A Prospective Observational Study of Clinico-Pathological Features, Prognostic Factors and Treatment Response to Primary Therapy in Multiple Myeloma at a Tertiary Care Centre

Second-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia with Additional Chromosomal Abnormalities

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only